Patent · US Active

Engineered CRISPR-Cas9 nucleases with altered PAM specificity

US11220678B2 · kind B2 · utility

1Cited by

3References

23Claims

0Family size

Assignee

The General Hospital Corporation · US

Inventors

J. Keith Joung · Winchester, US
Benjamin Kleinstiver · Medford, US

Key dates

Filing date	Sep 4, 2020
Grant date	Jan 11, 2022
Priority date	—
Expiry date	Sep 4, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2800/80
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.